Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases)

Author(s): Vittorio Briganti, Vincenzo Cuccurullo*, Valentina Berti, Giuseppe D. Di Stasio, Flavia Linguanti, Francesco Mungai and Luigi Mansi

Volume 13, Issue 3, 2020

Page: [166 - 176] Pages: 11

DOI: 10.2174/1874471013666191230143610

Abstract

Neuroendocrine tumors (NETs) consist of a relatively rare spectrum of malignancies that can arise from neuroendocrine cells; lung NETs (L-NETs) represent about 25% of primary lung neoplasm and 10% of all carcinoid tumors. Diagnostic algorithm usually takes into consideration chest Xray, contrast-enhanced CT and MRI. Nuclear medicine plays a crucial role in the detection and correct assessment of neoplastic functional status as it provides in vivo metabolic data related to the overexpression of Somatostatin Receptors (SSTRs) and also predicting response to peptide receptor radionuclide therapy (PRRT). 111In-Pentreotide (Octreoscan®) is commercially available for imaging of neuroendocrine tumors, their metastases and the management of patients with NETs. More recently, 99mTc-EDDA/HYNIC-TOC(Tektrotyd®) was introduced into the market and its use has been approved for imaging of patients with L-NETs and other SSTR-positive tumors. 99mTc-EDDA/HYNIC-TOC could also represent a good alternative to 68Ga-DOTA-peptides (DOTA-TOC, DOTA-NOC, DOTATATE) in hospitals or centers where PET/CT or 68Ge/68Ga generators are not available. When compared to 111In-Pentetreotide, Tektrotyd® showed slightly higher sensitivity, in the presence of higher imaging quality and lower radiation exposure for patients. Interesting perspectives depending on the kinetic analysis allowed by Tektrotyd® may be obtained in differential diagnosis of non-small cells lung cancer (NSCLC) versus small cells lung cancer (SCLC) and NETs. An interesting perspective could be also associated with a surgery radio-guided by Tektrotyd® in operable lung tumors, including either NETs and NSCLC.

Keywords: Neuroendocrine tumors, lung, nuclear medicine, PET/CT, diagnostic imaging, somatostatin, 99mTc-EDDA/HYNICTOC.

« Previous Next »
Graphical Abstract

[1]
Reid, M.D.; Balci, S.; Saka, B.; Adsay, N.V. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr. Pathol., 2014, 25(1), 65-79.
[http://dx.doi.org/10.1007/s12022-013-9295-2] [PMID: 24430597]
[2]
Woltering, E.A. American Joint Committee on Cancer 2017.AJCC Cancer Staging Manual, 8th ed; Amin, M.B., Ed.; Springer, 2017, pp. 351-359.
[http://dx.doi.org/10.1007/978-3-319-40618-3_29]
[3]
Cameselle-Teijeiro, J.M.; Mato Mato, J.A.; Fernández Calvo, O.; García Mata, J. Neuroendocrine Pulmonary Tumors of Low, Intermediate and High Grade: Anatomopathological Diagnosis-Prognostic and Predictive Factors. Mol. Diagn. Ther., 2018, 22(2), 169-177.
[http://dx.doi.org/10.1007/s40291-018-0315-2] [PMID: 29427124]
[4]
Pelosi, G.; Sonzogni, A.; Harari, S.; Albini, A.; Bresaola, E.; Marchiò, C.; Massa, F.; Righi, L.; Gatti, G.; Papanikolaou, N.; Vijayvergia, N.; Calabrese, F.; Papotti, M. Classification of pulmonary neuroendocrine tumors: new insights. Transl. Lung Cancer Res., 2017, 6(5), 513-529.
[http://dx.doi.org/10.21037/tlcr.2017.09.04] [PMID: 29114468]
[5]
Filosso, P.L.; Falcoz, P.E.; Solidoro, P.; Pellicano, D.; Passani, S.; Guerrera, F.; Ruffini, E. ESTS Lung Neuroendocrine Working-Group Participating Centers*. The European Society of Thoracic Surgeons (ESTS) lung neuroendocrine tumors (NETs) database. J. Thorac. Dis., 2018, 10(Suppl. 29), S3528-S3532.
[http://dx.doi.org/10.21037/jtd.2018.04.104] [PMID: 30510790]
[6]
Kim, J.Y.; Hong, S.M.; Ro, J.Y. Recent updates on grading and classification of neuroendocrine tumors. Ann. Diagn. Pathol., 2017, 29, 11-16.
[http://dx.doi.org/10.1016/j.anndiagpath.2017.04.005] [PMID: 28807335]
[7]
Jacobs, M.A.; Weinstein, S.; Hope, T.A.; Aslam, R.; Yee, J.; Coakley, F. Neuroendocrine tumors: beyond the abdomen. J. Comput. Assist. Tomogr., 2014, 38(6), 898-914.
[http://dx.doi.org/10.1097/RCT.0000000000000140] [PMID: 25162290]
[8]
Cuccurullo, V.; Faggiano, A.; Scialpi, M.; Cascini, G.L.; Piunno, A.; Catalano, O.; Colao, A.; Mansi, L. Questions and answers: what can be said by diagnostic imaging in neuroendocrine tumors? Minerva Endocrinol., 2012, 37(4), 367-377.
[PMID: 23235192]
[9]
Reubi, J.C.; Waser, B.; Schaer, J.C.; Laissue, J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med., 2001, 28(7), 836-846.
[http://dx.doi.org/10.1007/s002590100541] [PMID: 11504080]
[10]
Reubi, J.C.; Laissue, J.A.; Waser, B.; Steffen, D.L.; Hipkin, R.W.; Schonbrunn, A. Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts. J. Clin. Endocrinol. Metab., 1999, 84(8), 2942-2950.
[PMID: 10443702]
[11]
Desai, H.; Borges-Neto, S.; Wong, T.Z. Molecular Imaging and Therapy for Neuroendocrine Tumors. Curr. Treat. Options Oncol., 2019, 20(10), 78.
[http://dx.doi.org/10.1007/s11864-019-0678-6] [PMID: 31468190]
[12]
Krenning, E.P.; de Jong, M.; Kooij, P.P.; Breeman, W.A.; Bakker, W.H.; de Herder, W.W.; van Eijck, C.H.; Kwekkeboom, D.J.; Jamar, F.; Pauwels, S.; Valkema, R. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann. Oncol., 1999, 10(2), S23-S29.
[13]
Mansi, L.; Cuccurullo, V. Diagnostic imaging in neuroendocrine tumors. J. Mucl. Med., 2014, 55(10), 1576-1577.
[http://dx.doi.org/10.2967/jnumed.114.147082]
[14]
Cuccurullo, V.; Prisco, M.R.; Di Stasio, G.D.; Mansi, L. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers. Curr. Radiopharm., 2017, 10(2), 74-84.
[http://dx.doi.org/10.2174/1874471010666170323115136] [PMID: 28332450]
[15]
Rufini, V.; Calcagni, M.L.; Baum, R.P. Imaging of neuroendocrine tumors. Semin. Nucl. Med., 2006, 36(3), 228-247.
[http://dx.doi.org/10.1053/j.semnuclmed.2006.03.007] [PMID: 16762613]
[16]
Cascini, G.L.; Cuccurullo, V.; Tamburrini, O.; Rotondo, A.; Mansi, L. Peptide imaging with somatostatin analogues: more than cancer probes. Curr. Radiopharm., 2013, 6(1), 36-40.
[http://dx.doi.org/10.2174/1874471011306010006] [PMID: 23470033]
[17]
Ambrosini, V.; Morigi, J.J.; Nanni, C.; Castellucci, P.; Fanti, S. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP). The Quarterly J. Mucl. Med. Mol. Imaging, 2015, 59(1), 58-69.
[18]
Cascini, G.L.; Cuccurullo, V.; Mansi, L. The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology. Q. J. Nucl. Med. Mol. Imaging, 2010, 54(1), 24-36.
[PMID: 20168284]
[19]
Cuccurullo, V.; Mansi, L. Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(8), 1262-1265.
[http://dx.doi.org/10.1007/s00259-012-2156-2] [PMID: 22644715]
[20]
Ambrosini, V.; Nanni, C.; Fanti, S. The use of gallium-68 labeled somatostatin receptors in PET/CT imaging. PET Clin., 2014, 9(3), 323-329.
[http://dx.doi.org/10.1016/j.cpet.2014.03.008] [PMID: 25030395]
[21]
Cuccurullo, V.; Di Stasio, G.D.; Evangelista, L.; Castoria, G.; Mansi, L. Biochemical and pathophysiological premises to positron emission tomography with choline radiotracers. J. Cell. Physiol., 2017, 232(2), 270-275.
[http://dx.doi.org/10.1002/jcp.25478] [PMID: 27381438]
[22]
Kayani, I.; Conry, B. G.; Groves, A. M.; Win, T.; Dickson, J.; Caplin, M.; Bomanji, J. B. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J. Mucl. Med.,: official publication, Society of Nuclear Medicine 2009, 50(12), 1927-1932.
[23]
Cuccurullo, V.; Di Stasio, G.D.; Prisco, M.R.; Mansi, L. Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs? Indian J. Radiol. Imaging, 2017, 27(4), 509-516.
[PMID: 29379249]
[24]
Binderup, T.; Knigge, U.; Loft, A.; Mortensen, J.; Pfeifer, A.; Federspiel, B.; Hansen, C. P.; Hojgaard, L.; Kjaer, A. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J. Mucl. Med.,: official publication, Society of Nuclear Medicine, 2010, 51(5), 704-712.
[25]
Briganti, V.; Cuccurullo, V.; Di Stasio, G.D.; Mansi, L. Gamma emitters in pancreatic endocrine tumors imaging: is there a clinical space for 99mTc-peptides? Curr. Radiopharm., 2019, 12(2), 156-170.
[http://dx.doi.org/10.2174/1874471012666190301122524] [PMID: 30827276]
[26]
Cuccurullo, V.; Di Stasio, G.D.; Mansi, L. Physiopathological premises to Nuclear Medicine Imaging and therapy of pancreatic neuroendo-crine tumours. Curr. Radiopharm., In Press
[27]
Bodei, L.; Ferone, D.; Grana, C.M.; Cremonesi, M.; Signore, A.; Dierckx, R.A.; Paganelli, G. Peptide receptor therapies in neuroendocrine tumors. J. Endocrinol. Invest., 2009, 32(4), 360-369.
[http://dx.doi.org/10.1007/BF03345728] [PMID: 19636207]
[28]
Virgolini, I.; Innsbruck, T. Innsbruck Team. Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment? Eur. J. Nucl. Med. Mol. Imaging, 2015, 42(13), 1949-1954.
[http://dx.doi.org/10.1007/s00259-015-3153-z] [PMID: 26268679]
[29]
Bodei, L.; Cremonesi, M.; Kidd, M.; Grana, C.M.; Severi, S.; Modlin, I.M.; Paganelli, G. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Thorac. Surg. Clin., 2014, 24(3), 333-349.
[http://dx.doi.org/10.1016/j.thorsurg.2014.04.005] [PMID: 25065935]
[30]
Kitson, S.L.; Cuccurullo, V.; Moody, T.S.; Mansi, L. Radionuclide antibody-conjugates, a targeted therapy towards cancer. Curr. Radiopharm., 2013, 6(2), 57-71.
[http://dx.doi.org/10.2174/1874471011306020001] [PMID: 23808764]
[31]
Cascini, G.L.; Cuccurullo, V.; Tamburrini, O.; Mansi, L.; Rotondo, A. Nuclear medicine in multiple myeloma -- more than diagnosis. Nucl. Med. Rev. Cent. East. Eur., 2010, 13(1), 32-38.
[PMID: 21154314]
[32]
Mansi, L.; Cuccurullo, V.; Ciarmiello, A. From Homo sapiens to Homo in nexu (connected man): could functional imaging redefine the brain of a “new human species”? Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(7), 1385-1387.
[http://dx.doi.org/10.1007/s00259-014-2765-z] [PMID: 24737118]
[33]
Baum, R.P.; Kulkarni, H.R.; Carreras, C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin. Nucl. Med., 2012, 42(3), 190-207.
[http://dx.doi.org/10.1053/j.semnuclmed.2012.01.002] [PMID: 22475428]
[34]
Kwekkeboom, D.J.; Kam, B.L.; van Essen, M.; Teunissen, J.J.; van Eijck, C.H.; Valkema, R.; de Jong, M.; de Herder, W.W.; Krenning, E.P. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer, 2010, 17(1), R53-R73.
[http://dx.doi.org/10.1677/ERC-09-0078] [PMID: 19995807]
[35]
Upadhyay, B.; Lu, S.J.; Navalkissoor, S.; Gnanasegaran, G.; Buscombe, J. The imaging of neuroendocrine tumors using single photon emission computed tomography/computed tomography. The quarterly J. Mucl. Med. Mol. Imaging, 2015, 59(2), 140-151.
[36]
Win, Z.; Al-Nahhas, A.; Rubello, D.; Gross, M.D. Somatostatin receptor PET imaging with Gallium-68 labeled peptides. The quarterly J. Mucl. Med. Mol. Imaging, 2007, 51(3), 244-250.
[37]
Bakker, W.H.; Breeman, W.A.; Kwekkeboom, D.J.; De Jong, L.C.; Krenning, E.P. Practical aspects of peptide receptor radionuclide ther-apy with [177Lu][DOTA0, Tyr3]octreotate. The Quarterly J. Mucl. Med. Mol. Imaging, 2006, 50(4), 265-271.
[38]
Kitson, S.L.; Cuccurullo, V.; Ciarmiello, A.; Mansi, L. Targeted Therapy Towards Cancer-A Perspective. Anticancer. Agents Med. Chem., 2017, 17(3), 311-317.
[http://dx.doi.org/10.2174/1871520616666160926115008] [PMID: 27671296]
[39]
Mikołajczak, R.; Maecke, H.R. Radiopharmaceuticals for somatostatin receptor imaging. Nucl. Med. Rev. Cent. East. Eur., 2016, 19(2), 126-132.
[http://dx.doi.org/10.5603/NMR.2016.0024] [PMID: 27479790]
[40]
Cuccurullo, V.; Di Stasio, G.D.; Schillirò, M.L.; Mansi, L. Small-Animal Molecular Imaging for Preclinical Cancer Research. μPET and &#956.SPECT. Curr. Radiopharm., 2016, 9(2), 102-113.
[http://dx.doi.org/10.2174/1874471008666151027154148] [PMID: 26503290]
[41]
Maina, T.; Cescato, R.; Waser, B.; Tatsi, A.; Kaloudi, A.; Krenning, E.P.; de Jong, M.; Nock, B.A.; Reubi, J.C. [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors. J. Med. Chem., 2014, 57(15), 6564-6571.
[http://dx.doi.org/10.1021/jm500581d] [PMID: 25007399]
[42]
Tatsi, A.; Maina, T.; Cescato, R.; Waser, B.; Krenning, E.P.; de Jong, M.; Cordopatis, P.; Reubi, J.C.; Nock, B.A. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting. Eur. J. Med. Chem., 2014, 73, 30-37.
[http://dx.doi.org/10.1016/j.ejmech.2013.12.003] [PMID: 24378707]
[43]
Sowa-Staszczak, A.; Pach, D.; Mikołajczak, R.; Mäcke, H.; Jabrocka-Hybel, A.; Stefańska, A.; Tomaszuk, M.; Janota, B.; Gilis-Januszewska, A.; Małecki, M.; Kamiński, G.; Kowalska, A.; Kulig, J.; Matyja, A.; Osuch, C.; Hubalewska-Dydejczyk, A. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40(4), 524-531.
[http://dx.doi.org/10.1007/s00259-012-2299-1] [PMID: 23224740]
[44]
Reubi, J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev., 2003, 24(4), 389-427.
[http://dx.doi.org/10.1210/er.2002-0007] [PMID: 12920149]
[45]
Reubi, J.C.; Schär, J.C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J.S.; Mäcke, H.R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med., 2000, 27(3), 273-282.
[http://dx.doi.org/10.1007/s002590050034] [PMID: 10774879]
[46]
Smit Duijzentkunst, D.A.; Kwekkeboom, D.J.; Bodei, L. Somatostatin Receptor 2-Targeting Compounds. J. Nucl. Med., 2017, 58(Suppl. 2), 54S-60S.
[http://dx.doi.org/10.2967/jnumed.117.191015] [PMID: 28864613]
[47]
van der Lely, A.J.; de Herder, W.W.; Krenning, E.P.; Kwekkeboom, D.J. Octreoscan radioreceptor imaging. Endocrine, 2003, 20(3), 307-311.
[http://dx.doi.org/10.1385/ENDO:20:3:307] [PMID: 12721512]
[48]
Cuccurullo, V.; Cascini, G.L.; Tamburrini, O.; Mansi, L.; Rotondo, A. Less frequent requests for In-111 pentreotide and its brothers of endo-crinological interest. Minerva Endocrinol., 2011, 36(1), 41-52.
[PMID: 21460786]
[49]
Goldsmith, S.J. Update on nuclear medicine imaging of neuroendocrine tumors. Future Oncol., 2009, 5(1), 75-84.
[http://dx.doi.org/10.2217/14796694.5.1.75] [PMID: 19243300]
[50]
Briganti, V.; Matteini, M.; Ferri, P.; Vaggelli, L.; Castagnoli, A.; Pieroni, C. Octreoscan SPET evaluation in the diagnosis of pancreas neu-roendocrine tumors. Cancer Biother. Radiopharm., 2001, 16(6), 515-524.
[http://dx.doi.org/10.1089/10849780152752119] [PMID: 11789028]
[51]
Wang, F.; Wang, Z.; Yao, W.; Xie, H.; Xu, J.; Tian, L. Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging. J. Nucl. Med., 2007, 48(9), 1442-1448.
[http://dx.doi.org/10.2967/jnumed.107.040824] [PMID: 17704242]
[52]
Czepczyński, R.; Parisella, M.G.; Kosowicz, J.; Mikołajczak, R.; Ziemnicka, K.; Gryczyńska, M.; Sowiński, J.; Signore, A. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(10), 1635-1645.
[http://dx.doi.org/10.1007/s00259-007-0479-1] [PMID: 17530247]
[53]
Artiko, V.; Sobic-Saranovic, D.; Pavlovic, S.; Petrovic, M.; Zuvela, M.; Antic, A.; Matic, S.; Odalovic, S.; Petrovic, N.; Milovanovic, A.; Obradovic, V. The clinical value of scintigraphy of neuroendocrine tumors using (99m)Tc-HYNIC-TOC. J. BUON, 2012, 17(3), 537-542.
[PMID: 23033296]
[54]
Trogrlic, M.; Težak, S. Incremental value of 99mTc-HYNIC-TOC SPECT/CT over whole-body planar scintigraphy and SPECT in patients with neuroendocrine tumours. Nucl. Med. (Stuttg.), 2017, 56(3), 97-107.
[http://dx.doi.org/10.3413/Nukmed-0851-16-10] [PMID: 28164207]
[55]
Yamaga, L.Y.; Neto, G.C.; da Cunha, M.L.; Osawa, A.; Oliveira, J.C.; Fonseca, R.Q.; Nogueira, S.A.; Wagner, J.; Funari, M.G. 99mTc-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT. Radiol. Med. (Torino), 2016, 121(3), 225-228.
[http://dx.doi.org/10.1007/s11547-015-0593-2] [PMID: 26558391]
[56]
Cuccurullo, V.; Cascini, G.L.; Tamburrini, O.; Rotondo, A.; Mansi, L. Bone metastases radiopharmaceuticals: an overview. Curr. Radiopharm., 2013, 6(1), 41-47.
[http://dx.doi.org/10.2174/1874471011306010007] [PMID: 23470032]
[57]
Velikyan, I. 68Ga-Based radiopharmaceuticals: production and application relationship. Molecules, 2015, 20(7), 12913-12943.
[http://dx.doi.org/10.3390/molecules200712913] [PMID: 26193247]
[58]
Kulkarni, H.R.; Baum, R.P. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy. PET Clin., 2014, 9(1), 91-97.
[http://dx.doi.org/10.1016/j.cpet.2013.08.016] [PMID: 25029938]
[59]
Eberlein, U.; Lassmann, M. Dosimetry of [(6)(8)Ga]-labeled compounds. Appl. Radiat. Isot., 2013, 76, 70-74.
[60]
Reubi, J.C.; Waser, B.; Laissue, J.A.; Gebbers, J-O. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res., 1996, 56(8), 1922-1931.
[PMID: 8620515]
[61]
Reubi, J.C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo mul-tireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30(5), 781-793.
[http://dx.doi.org/10.1007/s00259-003-1184-3] [PMID: 12707737]
[62]
Barnett, P. Somatostatin and somatostatin receptor physiology. Endocrine, 2003, 20(3), 255-264.
[http://dx.doi.org/10.1385/ENDO:20:3:255] [PMID: 12721505]
[63]
Beyer, T.; Hacker, M.; Schubiger, A.; Virgolini, I.; Wester, H.J. Nuclear medicine 2013: from status quo to status go. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40(12), 1794-1796.
[http://dx.doi.org/10.1007/s00259-013-2570-0] [PMID: 24092263]
[64]
Del Gobbo, A.; Pellegrinelli, A.; Gaudioso, G.; Castellani, M.; Zito Marino, F.; Franco, R.; Palleschi, A.; Nosotti, M.; Bosari, S.; Vaira, V.; Ferrero, S. Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas. Histopathology, 2016, 68(5), 746-751.
[http://dx.doi.org/10.1111/his.12808] [PMID: 26272457]
[65]
Płachcińska, A.; Mikołajczak, R.; Kozak, J.; Rzeszutek, K.; Kuśmierek, J. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules. Nucl. Med. Rev. Cent. East. Eur., 2006, 9(1), 24-29.
[PMID: 16791800]
[66]
Kunikowska, J.; Lewington, V.; Krolicki, L. Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: The impact of 99mTc-HYNICTOC SPECT/SPECT/CT versus 68Ga-DOTATATE PET/CT upon clinical management. Clin. Nucl. Med., 2017, 42(12), 905-911.
[http://dx.doi.org/10.1097/RLU.0000000000001877] [PMID: 29076910]
[67]
Briganti, V.; Sestini, R.; Orlando, C.; Bernini, G.; La Cava, G.; Tamburini, A.; Raggi, C.C.; Serio, M.; Maggi, M. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin. Cancer Res., 1997, 3(12 Pt 1), 2385-2391.
[PMID: 9815638]
[68]
Etchebehere, E.C.; de Oliveira Santos, A.; Gumz, B.; Vicente, A.; Hoff, P.G.; Corradi, G.; Ichiki, W.A.; de Almeida Filho, J.G.; Cantoni, S.; Camargo, E.E.; Costa, F.P. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J. Nucl. Med., 2014, 55(10), 1598-1604.
[http://dx.doi.org/10.2967/jnumed.114.144543] [PMID: 25168627]
[69]
Artiko, V.; Afgan, A.; Petrović, J.; Radović, B.; Petrović, N.; Vlajković, M.; Šobić-Šaranović, D.; Obradović, V. Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC. Nucl. Med. Rev. Cent. East. Eur., 2016, 19(2), 99-103.
[http://dx.doi.org/10.5603/NMR.2016.0020] [PMID: 27479786]
[70]
Rossi, G.; Cavazza, A.; Spagnolo, P.; Sverzellati, N.; Longo, L.; Jukna, A.; Montanari, G.; Carbonelli, C.; Vincenzi, G.; Bogina, G.; Franco, R.; Tiseo, M.; Cottin, V.; Colby, T.V. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome. Eur. Respir. J., 2016, 47(6), 1829-1841.
[http://dx.doi.org/10.1183/13993003.01954-2015] [PMID: 27076588]
[71]
Koliakos, E.; Thomopoulos, T.; Abbassi, Z.; Duc, C.; Christodoulou, M. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a case report and review of the literature. Am. J. Case Rep., 2017, 18, 975-979.
[http://dx.doi.org/10.12659/AJCR.904468] [PMID: 28890532]
[72]
Melosky, B. Advanced typical and atypical carcinoid tumours of the lung: management recommendations. Curr. Oncol., 2018, 25(Suppl. 1), S86-S93.
[http://dx.doi.org/10.3747/co.25.3808] [PMID: 29910651]
[73]
Ramirez, R.A.; Chauhan, A.; Gimenez, J.; Thomas, K.E.H.; Kokodis, I.; Voros, B.A. Management of pulmonary neuroendocrine tumors. Rev. Endocr. Metab. Disord., 2017, 18(4), 433-442.
[http://dx.doi.org/10.1007/s11154-017-9429-9] [PMID: 28868578]
[74]
Bodei, L.; Ćwikla, J.B.; Kidd, M.; Modlin, I.M. The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuro-endocrine tumors. J. Thorac. Dis., 2017, 9(Suppl. 15), S1511-S1523.
[http://dx.doi.org/10.21037/jtd.2017.09.82] [PMID: 29201454]
[75]
Treglia, G.; Kroiss, A.S.; Piccardo, A.; Lococo, F.; Santhanam, P.; Imperiale, A. Role of positron emission tomography in thyroid and neuroendocrine tumours. Minerva Endocrinol., 2017, •••, S0391-S1977.
[76]
Beiderwellen, K.J.; Poeppel, T.D.; Hartung-Knemeyer, V.; Buchbender, C.; Kuehl, H.; Bockisch, A.; Lauenstein, T.C. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest. Radiol., 2013, 48(5), 273-279.
[http://dx.doi.org/10.1097/RLI.0b013e3182871a7f] [PMID: 23493121]
[77]
Mariniello, A.; Bodei, L.; Tinelli, C.; Baio, S.M.; Gilardi, L.; Colandrea, M.; Papi, S.; Valmadre, G.; Fazio, N.; Galetta, D.; Paganelli, G.; Grana, C.M. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(3), 441-452.
[http://dx.doi.org/10.1007/s00259-015-3190-7] [PMID: 26392198]
[78]
Sabet, A.; Haug, A.R.; Eiden, C.; Auernhammer, C.J.; Simon, B.; Bartenstein, P.; Biersack, H.J.; Ezziddin, S. Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. Am. J. Nucl. Med. Mol. Imaging, 2017, 7(2), 74-83.
[PMID: 28533939]
[79]
Cuccurullo, V.; Di Stasio, G.D.; Mansi, L. Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs. Nucl. Med. Rev. Cent. East. Eur., 2017, 20(1), 49-56.
[http://dx.doi.org/10.5603/NMR.2017.0003] [PMID: 28218348]

Rights & Permissions Print Cite
Article Metrics
18
© 2024 Bentham Science Publishers | Privacy Policy